IMmotion151: A randomized phase III study of atezolizumab plus bevacizumab vs sunitinib in untreated metastatic Renal Cell Carcinoma (mRCC)
Grullich, C Motzer, RJ Powles, T Atkins, M Escudier, BJ McDermott, D Suarez, C Bracarda, S Stadler, W Donskov, F
Grullich, C
Motzer, RJ
Powles, T
Atkins, M
Escudier, BJ
McDermott, D
Suarez, C
Bracarda, S
Stadler, W
Donskov, F
Citations
Altmetric:
Abstract
Description
Date
2018
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Grullich C, Motzer RJ, Powles T, Atkins M, Escudier BJ, McDermott D, et al. IMmotion151: A randomized phase III study of atezolizumab plus bevacizumab vs sunitinib in untreated metastatic Renal Cell Carcinoma (mRCC). Oncology Research and Treatment. 2018.